SCHEMBL2232274

SCHEMBL2232274

Cc1ccc(CCOc2ccc(C=O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
MAPT P10636 2/20 0.61
HPGD P15428 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
LMNA P02545 1/20 0.61
CYP2A6 P11509 2/20 0.53
KCNH2 Q12809 1/20 0.51
KDM4E B2RXH2 1/20 0.50
PPARA Q07869 2/20 0.48
PPARD Q03181 1/20 0.48
MAOA P21397 2/20 0.48
MAOB P27338 2/20 0.48
DRD2 P14416 2/20 0.48
DRD4 P21917 2/20 0.48
DRD3 P35462 2/20 0.48
PPARG P37231 1/20 0.46
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231854 1.00 ALDH1A1 (0.61) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL2234510 0.92 ALDH1A1 (0.64) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL2231178 0.87 ALDH1A1 (0.66) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL2232493 0.87 ALDH1A1 (0.63) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL2231514 0.87 ALDH1A1 (0.63) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL8390283 0.86 ALDH1A1 (0.69) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL14173881 0.86 KCNH2 (0.65) SMN1; SMN2KCNH2PPARAPPARDMAOA
SCHEMBL4048717 0.85 ALDH1A1 (0.58) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL2232877 0.85 ALDH1A1 (0.58) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL27900832 0.84 KCNH2 (0.62) SMN1; SMN2KCNH2PPARAPPARDMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2021-04-01 US claimed
EP-3763728-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) 2021-01-13 EP claimed
WO-2019170046-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海来益生物药物研究开发中心有限责任公司 2019-09-12 WO claimed
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2023-07-11 US disclosed
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2021-04-01 US disclosed
EP-3763728-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) 2021-01-13 EP disclosed
WO-2019170046-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海来益生物药物研究开发中心有限责任公司 2019-09-12 WO disclosed
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
EP-2528897-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS Otsuka Pharmaceutical Co., Ltd. (JP) 2012-12-05 EP disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
WO-2011093524-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof VIP, CUTA, MGAM ALDH1A1 4289/4885MAPT 3389/4885HPGD 3146/4885
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof VIP, CUTA, MGAM ALDH1A1 4289/4885MAPT 3389/4885HPGD 3146/4885
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 ALDH1A1 314/4885MAPT 4703/4885HPGD 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.